Is VTGN or XBIO more undervalued in 2026?

CirclFi compares VistaGen Therapeutics, Inc. (VTGN) and Xenetic Biosciences, Inc. (XBIO) using 13 institutional-grade valuation models. VTGN has a Quality of Company score of 6.0/10 while XBIO scores 6.6/10.

Which is a better buy — VTGN or XBIO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do VTGN and XBIO valuations compare?

VTGN at $0.63 and XBIO at $3.08 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

VTGN vs XBIO Valuation Comparison 2026 — Intrinsic Value Analysis

VTGN

Biotechnology

VistaGen Therapeutics, Inc.

Quality

6.0

out of 10

Value Trap

LOW

Price

$0.63

Last close

Models

9/13

Active

XBIO

Biotechnology

Xenetic Biosciences, Inc.

Quality

6.6

out of 10

Value Trap

SAFE

Price

$3.08

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	VTGN Fair Value	VTGN Upside	XBIO Fair Value	XBIO Upside
Bayesian DCF	Intrinsic	$0.81	+27.9%	$2.58	-16.2%
Earnings Power Value	Intrinsic	—	—	$2.84	-4.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$2.62	+313.1%	$10.00	+224.6%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for VTGN vs XBIO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

VTGN vs XBIO — Which Stock Is More Undervalued?

XBIO scores higher with a 6.6/10 quality rating vs VTGN's 6.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing VistaGen Therapeutics, Inc. (VTGN) and Xenetic Biosciences, Inc. (XBIO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

VTGN currently trades at $0.63 with a QOC of 6.0/10, while XBIO trades at $3.08 with a QOC of 6.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).